This test may be ordered during the initial workup of a person who has been diagnosed with multiple myeloma in order to stage the disease and periodically to evaluate disease activity and monitor the effectiveness of treatment. It may sometimes be ordered when a person has myeloma or lymphoma to help determine their likely prognosis. A CSF B2M may rarely be ordered when a healthcare practitioner suspects that a disease such as lymphoma is affecting someone's central nervous system.
Increased levels of B2M in the blood and/or urine indicate that there is a problem, but they are not diagnostic of a specific disease or condition. They do, however, reflect disease activity and the amount of cancer present. When someone has been diagnosed with multiple myeloma or lymphoma, that person is likely to have a poorer prognosis if the B2M level is significantly elevated.
For monitoring treatment, decreasing levels over time in someone with multiple myeloma indicate that the person is responding to treatment. Stable or increasing levels indicate that the person is not responding.
Increases in the CSF in someone with a disease such as HIV/AIDS indicate likely central nervous system involvement.
Low levels of B2M are considered normal. B2M may be undetectable in the urine and CSF.
Not much of precautions is needed. only you have to avoid the direct contact with blood of the patient. moreover, the patient may feel pain while drawing the blood out in blood tests. Other imaging techniques do not require any special precautions.
Test Method 1 : The beta-2 microglobulin test is a blood test. A nurse or technician will draw your blood from a vein near your elbow or hand. This blood will be collected in a tube and sent to a lab for analysis. There the amount of beta-2 microglobulin is find.
Your doctor will contact you to explain your results when they become available.
Report available : The turn around time for this test is around 24 hours.